

# Takako Inoue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1821569/publications.pdf>

Version: 2024-02-01

26  
papers

622  
citations

840119

11  
h-index

610482

24  
g-index

27  
all docs

27  
docs citations

27  
times ranked

942  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut Dysbiosis Associated With Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 869-877.	2.9	130
2	Novel biomarkers for the management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 261-279.	4.5	79
3	Hepatitis B virus and its sexually transmitted infection “an update. <i>Microbial Cell</i> , 2016, 3, 419-436.	1.4	76
4	Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. <i>Journal of Hepatology</i> , 2021, 75, 302-310.	1.8	56
5	Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. <i>Hepatology Research</i> , 2020, 50, 840-852.	1.8	46
6	The Role of Hepatitis B Core-Related Antigen. <i>Genes</i> , 2019, 10, 357.	1.0	40
7	High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. <i>Journal of Gastroenterology</i> , 2018, 53, 883-889.	2.3	33
8	Cross-Protection of Hepatitis B Vaccination among Different Genotypes. <i>Vaccines</i> , 2020, 8, 456.	2.1	29
9	Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus. <i>Hepatology Research</i> , 2018, 48, E203-E212.	1.8	26
10	Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. <i>International Journal of Molecular Sciences</i> , 2020, 21, 949.	1.8	26
11	Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. <i>Microorganisms</i> , 2021, 9, 2083.	1.6	16
12	Novel strategies for the early diagnosis of hepatitis B virus reactivation. <i>Hepatology Research</i> , 2021, 51, 1033-1043.	1.8	12
13	Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection. <i>Liver International</i> , 2022, 42, 124-134.	1.9	11
14	Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assay. <i>Hepatology Research</i> , 2022, 52, 745-753.	1.8	8
15	Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker <i>Wisteria floribunda</i> Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) in Chronic Hepatitis C with Advanced Fibrosis. <i>Japanese Journal of Infectious Diseases</i> , 2018, 71, 177-183.	0.5	5
16	Clinical usefulness of a newly developed high-sensitive hepatitis B surface antigen (HBsAg) assay for monitoring hepatitis B reactivation. <i>Acta Hepatologica Japonica</i> , 2019, 60, 237-247.	0.0	5
17	Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0263844.	1.1	5
18	Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation. <i>Journal of Gastroenterology</i> , 2022, 57, 486-494.	2.3	5

#	ARTICLE	IF	CITATIONS
19	Present status of hepatitis medical care coordinators in regional core centers in Japan. Acta Hepatologica Japonica, 2021, 62, 96-98.	0.0	3
20	Reply to: "Understanding HBcrAg components improves the interpretation of clinical HBcrAg assay results". Journal of Hepatology, 2021, 75, 998-999.	1.8	3
21	Recommendation of medical consultation and/or treatment by pharmacists to patients with chronic hepatitis C who visited health insurance pharmacies. Acta Hepatologica Japonica, 2017, 58, 639-642.	0.0	2
22	Design and outcome of a novel strategy against viral hepatitis, developed by Aichi Dental Association. Acta Hepatologica Japonica, 2021, 62, 588-589.	0.0	2
23	Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. PLoS ONE, 2017, 12, e0170667.	1.1	2
24	Clinical Evaluation of a Newly Developed Chemiluminescent Enzyme Immunoassay for Hepatitis C Virus Core Antigen in Japan. Japanese Journal of Infectious Diseases, 2019, 72, 285-291.	0.5	1
25	In-depth interviews of non-hepatologists and the achievements made after introducing a "patient referral document for hepatitis" in our hospital. Acta Hepatologica Japonica, 2019, 60, 219-228.	0.0	1
26	New role for hepatitis medical care coordinator training course proposed by Aichi Dental Association. Acta Hepatologica Japonica, 2022, 63, 346-349.	0.0	0